Regent Pacific (00575) has announced that its wholly-owned subsidiary Deep Longevity, Inc. and its affiliates (collectively, "Deep Longevity") will launch Accrua™, its consumer digital health and telemedicine platform, in the United States in October 2026.

Accrua will be available to consumers across all 50 U.S. states from the launch date. As set out in the company's interim results announcement and interim report for 2026 dated August 25, 2026, the launch represents the culmination of Deep Longevity's strategy to expand its presence in the U.S. market through direct-to-consumer ("D2C") digital telemedicine services. The board considers Accrua a potentially transformative development for the group and an important new future revenue stream that complements Deep Longevity's existing business-to-business ("B2B") model.

Accrua offers simple, direct online medical services led by licensed U.S. clinicians. At its core is Deep Longevity's proprietary, AI-generated BloodAge report, which uses routine blood tests to determine whether a consumer is an "accelerated ager" — someone whose biological age advances faster than their chronological age. Following clinician consultation, Accrua provides a range of physician-guided treatment options, including weight loss (such as glucagon-like peptide-1 ("GLP-1") therapy), peptides, women's health (such as hormone replacement therapy) and men's health (such as testosterone therapy). In each case, the initial treatment plan and subsequent adjustments are personalized by licensed clinicians and based on the user's BloodAge report, rather than relying on self-reported symptoms or a single biomarker. Users remeasure their BloodAge quarterly, allowing them and their clinicians to track treatment effects based on objective, science-based indicators of biological aging rather than symptoms or weight alone.

Accrua is positioned around a simple idea — "You know your age. Your blood knows better." — offering quarterly biological age measurement, clinician-guided treatment plans and compounded therapies as a comprehensive longevity care program backed by peer-reviewed science. The platform's initial categories include weight loss, women's health and men's health, with more categories planned.

Accrua extends Deep Longevity's deep learning aging clock technology and SenoClock® platform directly to consumers for the first time, while continuing Deep Longevity's existing collaborations with clinics, hospitals, laboratories and insurers. The board believes Accrua differentiates itself from other U.S. digital telemedicine platforms through the peer-reviewed, independent clinical research underpinning Deep Longevity's technology. Deep Longevity's BloodAge model was the subject of a peer-reviewed study by Goshen et al. published in Aging and Disease (2026), which followed approximately 2,600 adults over a mean of 9.2 years; after adjusting for age, sex, body mass index ("BMI"), smoking and hypertension, each additional year of gap between biological and chronological age was independently associated with a 15% higher risk of mortality and a 6% higher risk of hospitalization. Deep Longevity's technology has also received notable external recognition, most recently winning runner-up in the Nestlé VITAL Intelligent Aging Global Challenge, a global innovation competition that attracted 150 companies worldwide.

Accrua is entering the U.S. consumer digital health market, where platforms focused on related health and wellness areas have already generated substantial revenue. For example, according to The New York Times (April 2, 2026), MEDVi, LLC, a U.S. digital telemedicine platform focused on GLP-1 weight loss and related therapies, generated more than US$400 million in revenue in 2025, its first full operating year, and on current trends its annualized revenue for 2026 could reach approximately US$1.8 billion (Forbes, April 2, 2026, citing The New York Times). Accrua covers a similar range of product categories. While there is no guarantee that Accrua will achieve comparable results, the board believes these figures illustrate the scale of consumer demand and revenue potential in the market Accrua is targeting.

Accrua is built on a capital-efficient model. Clinical service delivery will be provided by existing U.S. telemedicine infrastructure partners through networks of independently licensed physicians, pharmacies and compounding partners, covering clinician consultations, prescribing, pharmacy dispensing and delivery, patient enrollment and patient portals, electronic health records, billing and payment processing, secure video consultations and patient communications, across all 50 U.S. states. This model allows Deep Longevity to scale nationwide from the launch date without owning clinical infrastructure or directly bearing drug inventory. Revenue is expected to come primarily from subscriptions and to be recurring in nature. The launch will be supported by targeted digital marketing campaigns, initially focused on selected U.S. states, to optimize customer acquisition before further scaling.

The board is deeply excited about the launch of Accrua. Accrua brings together Deep Longevity's world-class aging clock technology, independent peer-reviewed scientific research and a proven, scalable telemedicine delivery model to enter one of the largest and fastest-growing categories in the U.S. consumer healthcare market. The board believes Accrua has the potential to become a significant driver of the group's revenue growth and to create meaningful long-term value for shareholders, and it looks forward to updating shareholders on Accrua's progress following launch. Mr. Jamie Gibson, Executive Director and Chief Executive Officer of the company, said, "The launch of Accrua is a milestone moment for Deep Longevity and the group. For the first time, consumers across the United States will have direct access to our BloodAge science and to personalized care provided by licensed clinicians. We believe that basing treatment on biological age rather than symptoms alone is a genuinely novel proposition in a market that has already demonstrated extraordinary consumer demand, and we are excited about the opportunities ahead."